Terms: = Ovarian cancer AND ATP1A1, P05023, MGC51750, MGC3285, ENSG00000163399, 476 AND Prognosis
8 results:
1. Breast density reduction as a predictor for prognosis in premenopausal women with estrogen receptor-positive breast cancer: an exploratory analysis of the updated ASTRRA study.
Bae SJ; Kim HJ; Kim HA; Ryu JM; Park S; Lee EG; Im SA; Jung Y; Park MH; Park KH; Kang SH; Park E; Kim SY; Lee MH; Kim LS; Lee A; Noh WC; Gwark S; Kim S; Jeong J
Int J Surg; 2024 Feb; 110(2):934-942. PubMed ID: 38000057
[TBL] [Abstract] [Full Text] [Related]
2. PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis.
Millán-de-Meer M; Luque-Ramírez M; Nattero-Chávez L; Escobar-Morreale HF
Hum Reprod Update; 2023 Nov; 29(6):741-772. PubMed ID: 37353908
[TBL] [Abstract] [Full Text] [Related]
3. Long non-coding RNA FOXP4-AS1 is a prognostic biomarker and associated with immune infiltrates in ovarian serous cystadenocarcinoma.
Liao C; Wang A; Ma Y; Liu H
Medicine (Baltimore); 2021 Oct; 100(40):e27473. PubMed ID: 34622876
[TBL] [Abstract] [Full Text] [Related]
4. Higher platelet distribution width is associated with unfavorable prognosis in ovarian cancer.
Qin L; Li JY; Huang WJ; Zhang ML; Wang RT; Shen W
Cancer Biomark; 2020; 28(3):365-370. PubMed ID: 32417761
[TBL] [Abstract] [Full Text] [Related]
5. Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis.
Kim TH; Kim HS; Kim TJ; Chang SJ; Kim DY; Ryu SY; Kim BG; Kim YT; Bae DS; Ryu HS; Nam JH
Gynecol Oncol; 2016 Jun; 141(3):440-446. PubMed ID: 27020700
[TBL] [Abstract] [Full Text] [Related]
6. Validation of a two-tier grading system in an unselected, consecutive cohort of serous ovarian cancer patients.
Battista MJ; Cotarelo C; Almstedt K; Heimes AS; Makris GM; Weyer V; Schmidt M
Arch Gynecol Obstet; 2016 Sep; 294(3):599-606. PubMed ID: 26993518
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic value of Ca 125 levels during primary therapy.
Markmann S; Gerber B; Briese V
Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
[TBL] [Abstract] [Full Text] [Related]
8. [Impact of center characteristics on outcome in ovarian cancer in Germany].
du Bois A; Rochon J; Lamparter C; Pfisterer J
Zentralbl Gynakol; 2005 Feb; 127(1):18-30. PubMed ID: 15702447
[TBL] [Abstract] [Full Text] [Related]
